1. Home
  2. RSSS vs MNOV Comparison

RSSS vs MNOV Comparison

Compare RSSS & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Research Solutions Inc

RSSS

Research Solutions Inc

HOLD

Current Price

$2.57

Market Cap

86.5M

ML Signal

HOLD

Logo Medicinova Inc

MNOV

Medicinova Inc

HOLD

Current Price

$1.47

Market Cap

69.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RSSS
MNOV
Founded
2006
2000
Country
United States
United States
Employees
N/A
6
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
86.5M
69.4M
IPO Year
2008
2004

Fundamental Metrics

Financial Performance
Metric
RSSS
MNOV
Price
$2.57
$1.47
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$5.00
$7.50
AVG Volume (30 Days)
45.2K
21.8K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
130.77
N/A
EPS
0.04
N/A
Revenue
$28,793,922.00
$2,360,807.00
Revenue This Year
$1.81
N/A
Revenue Next Year
$5.73
$180.00
P/E Ratio
$64.25
N/A
Revenue Growth
2.77
194.15
52 Week Low
$2.15
$1.17
52 Week High
$4.12
$1.96

Technical Indicators

Market Signals
Indicator
RSSS
MNOV
Relative Strength Index (RSI) 54.11 59.25
Support Level $2.48 $1.40
Resistance Level $2.60 $1.54
Average True Range (ATR) 0.11 0.04
MACD 0.01 0.01
Stochastic Oscillator 41.43 76.47

Price Performance

Historical Comparison
RSSS
MNOV

About RSSS Research Solutions Inc

Research Solutions Inc is a holding company. The company provides vertical software-as-a-service ("SaaS") and artificial intelligence ("AI") solutions, providing software and related services to help research-intensive organizations simplify the research process, save time, and money. The company operates in a single segment, which derives its revenue from subscription fees from its cloud-based SaaS Platforms and transactional service fees for the electronic delivery of single articles. The company generates the majority of its revenue from the Transactions. Geographically, the company generates the majority of its revenue from the United States, followed by Europe.

About MNOV Medicinova Inc

MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.

Share on Social Networks: